InvestorsHub Logo
Followers 28
Posts 12075
Boards Moderated 0
Alias Born 01/02/2003

Re: apollo1452 post# 144

Thursday, 10/03/2019 7:01:19 AM

Thursday, October 03, 2019 7:01:19 AM

Post# of 1201
Bottom line the Product Works and their is a significant market demand for it.

To understand last weeks PR read the following written by a guy with a PHD who understands this information well;

Sensitivity and specificity tell you how often the device makes a mistake. Great sensitivity means you catch all of the cases (you don't miss people who have the disease.) Great specificity means you don't accidentally tell people they have the disease when they don't.

That means MRI is really good at not telling people they have the disease, when they don't, but it misses a few cases. TAEUS is really good at finding all the cases, but accidentally tells people they have the disease when they don't.

Biopsy, is good at both, but means having someone poke a hole in you and pull out a piece of liver.

This is really good because we now have two complementary methods to screen for the disease. TAEUS will catch them all, and if they're not sure, they'll send them to MRI to confirm.

We actually don't care too much about accuracy of patients with less than 5% liver fat anyhow - they clearly don't need treatment.

"The Investors's Chief Problem--and even his worst enemy--is likely to be himself"
---Benjamin Graham

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NDRA News